Adverum Climbs Out Of Abyss With Promising Early Gene Therapy Data In Wet AMD

Preliminary Phase II data in wet age-related macular degeneration (wet AMD) give a leg up to Adverum Biotechnologies, Inc.’s ixoberogene soroparvovec (ixo-vec), its gene therapy for retinal diseases, as it looks set to compete closely with two rivals. The positive data were particularly important, coming after the company had to abandon the diabetic macular edema (DME) indication and restructure to focus on wet AMD.

The Redwood City, CA-based biotech presented the preliminary data from the LUNA study on 8 February at the Macula Society’s...